NovoCure Ltd director Martin J. Madden received new equity awards as part of his compensation. He was granted 11,610 ordinary shares in the form of restricted stock units, which are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.
He was also granted stock options covering 16,999 ordinary shares at an exercise price of $16.15 per share, expiring in 2036. These options will fully vest and become exercisable on the same schedule as the restricted stock units. Following the share grant, Madden directly holds 30,284 ordinary shares.
NovoCure Ltd director Vernon W. Anthony reported equity compensation awards. He received 11,610 ordinary shares in the form of restricted stock units that vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual general meeting of shareholders. He also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest and become exercisable on the same schedule and expire on June 3, 2036. Following these awards, he holds 209,267 ordinary shares directly.
NovoCure Ltd director Gabriel Leung reported a mandatory sale of 2,945 Ordinary Shares to cover taxes on vested Restricted Stock Units. The shares were sold on an open-market basis at a weighted average price of $15.7707 per share. According to the company’s equity incentive plan, this “sell to cover” transaction was required to satisfy tax withholding obligations and was not a discretionary trade by Leung. After the sale, he directly holds 89,499 NovoCure Ordinary Shares.
NovoCure Ltd director Kristin Stafford reported a mandated sale of 2,945 Ordinary Shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share to cover tax withholding obligations tied to vesting Restricted Stock Units.
The company’s equity incentive plan requires these tax payments to be funded through a “sell to cover” transaction, so this was not a discretionary trade. After the sale, Stafford directly holds 11,324 Ordinary Shares. The transaction was executed in multiple trades between $15.65 and $15.88 per share.
NovoCure Ltd director Allyson J. Ocean reported a mandated sale of ordinary shares linked to equity compensation. On June 2, 2026, she sold 2,945 ordinary shares at a weighted average price of $15.7707 per share.
According to the disclosure, the shares were sold solely to cover tax withholding obligations from the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. Following this transaction, she directly holds 11,324 ordinary shares of NovoCure.
NovoCure Ltd director Timothy J. Scannell reported an open-market sale of 2,945 Ordinary Shares on June 2, 2026 at a weighted average price of $15.7707 per share. According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the transaction was mandated by a “sell to cover” provision rather than being a discretionary trade. After this sale, Scannell directly holds 14,288 Ordinary Shares of NovoCure.
NovoCure Ltd director Jeryl L. Hilleman reported a mandated sale of 2,945 ordinary shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share.
According to the disclosure, the sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. After this transaction, Hilleman directly holds 13,861 ordinary shares of NovoCure.
NovoCure Ltd director Vernon W. Anthony reported an open-market sale of 2,945 Ordinary Shares of NovoCure on June 2, 2026 at a weighted average price of $15.7707 per share. According to the footnotes, these shares were sold to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and did not represent a discretionary trade. After this transaction, Anthony directly holds 197,657 Ordinary Shares, indicating the sale was a small, routine adjustment for tax purposes rather than a significant change in his overall position.
NovoCure Ltd director David Hung reported a mandated share sale tied to equity compensation. On June 2, 2026, he disposed of 2,945 Ordinary Shares at a weighted average price of $15.7707 per share.
According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans, and the transaction "does not represent a discretionary trade". After the sale, Hung directly held 20,465 Ordinary Shares. The sale was executed in multiple trades between $15.65 and $15.88 per share.